Back to search results

Enasidenib for T-Cell Lymphoma with IDH2 Mutation

This study is looking at whether enasidenib is a safe treatment for people with a type of T-cell lymphoma called angioimmunoblastic T-cell lymphoma (AITL) that has a specific change in its cells called an IDH2 mutation. Researchers will study enasidenib by itself or in combination with another drug called rituximab. You could be eligible if you are 18 or older and have AITL with an IDH2 mutation. The study aims to see how many people respond to the treatment after one year. The current status of this study is unclear, and it plans to enroll about 25 people.

Study design
This is an interventional study with an unclear phase, planning to enroll 25 participants. It will test enasidenib alone or with rituximab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures response rate at 1 year, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06756308

A Study of Enasidenib in People With T-Cell Lymphoma

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~2 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:EnasidenibRituximab

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
response rate
Measured over 1 year

Conditions

T-cell Lymphoma

Explore related trials

Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeIDH2 Gene

Where it's being run

7 sites across 2 states
New Jersey4
New York3

Study leadership

  • Zachary Epstein-Peterson, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Revised International Working Group Classification for systemic lymphoma(13)
Atypical T lymphocytes quantifiable by flow cytometry or morphology in the peripheral blood or bone marrow 7. Women of reproductive potential\* must have a negative serum or urine β human chorionic gonadotropin (β-hCG) pregnancy test. All women of reproductive potential must agree to use adequate methods of birth control throughout the study and for 30 days after the last dose of study drug. \*A woman of reproductive potential is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) 8. Women must agree to not breastfeed during the study period 9. Male subjects must agree to practice true abstinence from sexual intercourse or to the use of highly effective contraceptive methods with non-pregnant female partners of childbearing potential at screening and throughout the course of the study, and should avoid conception with their partners during the course of the study and for 4 months following the last study treatment 10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements

What this trial measures

  • response rate1 year

    a 20% response rate is undesirable and 45% is desirable